Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Key claim: This early-phase trial is evaluating whether hyperbaric oxygen therapy is safe and can improve engraftment, GVHD outcomes, neutrophil recovery, and mucositis severity in patients with CMML, CNL, myelofibrosis, MDS/MPN overlap, and related myeloid malignancies undergoing allogeneic peripheral blood stem cell transplant.
Abstract
The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count, and incidence and severity of mucositis (inflammation of the mouth or gut) and infection. This study has two cohorts. The first cohort is subjects with acute myeloid leukemia (AML) or Myelodysplastic Syndrome (MDS). The second cohort is subjects with chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), chronic monocytic leukemia, chronic neutrophilic leukemia (CNL), myelofibrosis, and myelodysplastic/myeloproliferative (MDS/MPN) overlap syndrome. The first cohort has completed the recruitment so only the second cohort will be recruited.
Why this matters
HBOT is the first environmental oxygen exposure being formally tested in MPN-inclusive allo-HSCT populations, making this the only mpn-direct datapoint on the page despite being at trial-early maturity. If safety and engraftment signals hold, HBOT would shift from a mechanism-plausible curiosity (oxygen tension effects on HSC homing and mucosal healing) to an MPN-adjacent peri-transplant intervention, but until results read out the page must continue to frame HBOT as unproven.